PART I—FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
SYNAPTICS INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions, except par value and share amounts)
(unaudited)
March 2026
June 2025
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Property and equipment, net
Goodwill
Acquired intangible assets
Deferred tax assets
Non-current other assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued liabilities
Long-term debt
Other long-term liabilities
Stockholders' equity:
Preferred stock:
$0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock:
$0.001 par value; 120,000,000 shares authorized, 71,878,081 and 70,611,845 shares issued,
38,735,446 and 38,642,761 shares outstanding, at March 2026 and June 2025, respectively
Additional paid-in capital
Treasury stock: 33,142,635 and 31,969,084 common shares at March 2026 and June 2025, respectively, at cost
Retained earnings
Total stockholders' equity
Total liabilities and stockholders' equity
See accompanying notes to condensed consolidated financial statements (unaudited)
SYNAPTICS INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share data)
(unaudited)
Three Months Ended
Nine Months Ended
March
Net revenue
Cost of revenue
Gross margin
Operating expenses:
Research and development
Selling, general, and administrative